T. Rowe Price Associates
GNCA

T. Rowe Price Associates’s Genocea Biosciences, Inc. GNCA Stock Holding History

T. Rowe Price Associates’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,486
Closed -$187K – 2597
2017
Q2 		$187K Buy
4,486
+1,504
+50% +$72.4K ﹤0.01% 2396
2017
Q1 		$145K Buy
+2,982
New +$117K ﹤0.01% 2442

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

T. Rowe Price Associates's GNCA Position: Q3 2017 in Review

T. Rowe Price Associates sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2017, closing a stake of 4,486 shares — an estimated $187K sold.

T. Rowe Price Associates first reported a position in GNCA in Q1 2017 and held it in 2 quarters. The position peaked at $187K in Q2 2017. 62 funds tracked by Wall St. Rank hold GNCA as of Q3 2017.

  • T. Rowe Price Associates reported no remaining Genocea Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 4,486 Genocea Biosciences, Inc. shares in Q3 2017, an estimated $187K.
  • T. Rowe Price Associates first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 2 quarters.
  • T. Rowe Price Associates's Genocea Biosciences, Inc. position peaked at $187K in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2017.

Based on T. Rowe Price Associates's 13F filing for Q3 2017, filed 14 Nov 2017.